Akademik Veri Yönetim Sistemi
Mikrobiyoloji Bulteni, cilt.60, sa.2, ss.212-219, 2026 (SCI-Expanded, Scopus, TRDizin)
Vibrio cholerae is a gastrointestinal pathogen that causes waterborne epidemics. More than 200 serog-roups of V.cholerae have been identified to date. In general, 01 or 0139 strains of V.cholerae that produce cholera toxin cause acute, rapidly progressive watery diarrhea while non-O1/non-O139 strains that do not produce cholera toxin (non-toxigenic) can cause sporadic gastroenteritis, wound infection and septicemia. Although V.cholerae non-O1/O139 (NOVC) strains are not considered to have sufficient clinical significance due to their lack of toxin production and failure to cause epidemics, an increasing number of cases have been reported in the literature in recent years. In this report, a case of non-toxigenic V.cholerae bacteremia who presented to the emergency department of our hospital with chest pain was presented. A 59-year-old male patient with a medical history of gastrectomy secondary to gastric cancer (2006) and biliary tract surgery secondary to cholelithiasis (2016) presented to the emergency department with stabbing chest pain for three days. The patient was admitted to the coronary intensive care unit for follow-up with a prediagnosis of hypertrophic obstructive cardiomyopathy (HOCM). During the followup of the patient, blood culture was taken due to a fever of 39.2 °C accompanied by chills and shivering and empirical ceftriaxone and metronidazole treatment was started due to the presence of intrahepatic air density in abdominal tomography. His treatment was extended to meropenem after gram-negative bacilli were reported in blood culture in double vial. The microorganism reported in the follow-up was identified as V.cholerae by matrix-assisted laser desorption/ionization-time of flight mass spectrometry and VITEK 2 (bioMérieux, France) and the isolate was confirmed by the National Reference Laboratory for Enteric Pathogens of the Department of National Microbiology Reference Laboratories and Biological Products, General Directorate of Public Health of Türkiye. The treatment of the patient was revised as ceftriaxone 1 × 2 g and ciprofloxacin 2 × 400 mg intravenous, considering the antimicrobial susceptibility of the current isolate. The patient was admitted to the infectious diseases ward for further investigation and treatment after the preliminary diagnosis of HOCM was ruled out. The patient, in whom no growth was detected in the control blood culture taken during hospitalization and who did not have a recurrence of fever, was discharged with a treatment plan of ceftriaxone intramuscularly and ciprofloxacin orally for a total of 14 days. In conclusion, infections with NOVC species leading to sepsis are being reported in increasing numbers every day. Currently, there are no definitive guidelines for the treatment of NOVC bacteremia. Therefore, clinicians should increase their knowledge of NOVC bacteremia to rapidly diagnose and treat patients.